24/7 Market News Snapshot 18 February, 2025 – PainReform Ltd. Ordinary Shares (NASDAQ:PRFX)
DENVER, Colo., 18 February, 2025 (247marketnews.com) – (Nasdaq:PRFX) are discussed in this article.
PainReform Ltd. (Nasdaq:PRFX) is witnessing a significant surge in its stock price, which has soared to $4.978 in pre-market trading, reflecting an impressive 76.52% increase from its prior closing price of $2.82. This remarkable jump, accompanied by a robust trading volume of 9.64 million shares, indicates heightened investor enthusiasm and signals a potential upward trajectory for the company. Investors are closely monitoring this positive momentum as PainReform breaks through key resistance levels, presenting opportunities for potential investments amid optimistic market sentiment.
In addition to its stock performance, PainReform has announced a strategic acquisition that underscores its commitment to diversifying its business operations. The company has finalized a definitive agreement to acquire 100% of DeepSolar, an AI-driven solar analytics platform renowned for its innovative software solutions. The acquisition aims to enhance PainReform’s portfolio and capitalize on high-growth markets beyond its core pharmaceutical endeavors.
DeepSolar offers advanced analytics tools that help businesses and homeowners optimize their solar energy assets, boasting the capability to reduce operational costs by up to 30% while maximizing energy production. Its established presence in both commercial and residential sectors has garnered a substantial customer base, including major utility-scale solar operators.
Ehud Geller, Chairman of PainReform, expressed confidence in the acquisition, emphasizing the strategic alignment with the company’s vision for long-term growth and value creation for shareholders. He highlighted DeepSolar’s technology as a vital asset that positions PainReform to thrive in an evolving market landscape.
This acquisition not only enriches PainReform’s growth strategy but also signifies its intent to leverage operational synergies that extend beyond its pharmaceutical focus—setting the stage for dynamic developments in the company’s trajectory as it positions itself at the intersection of medicines and renewable energy solutions.